Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells

References

• Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171–7
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood 1997; 89: 3129–35
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673–9
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C, Germain RN. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 1995; 182: 841–51
   PubMed Web of Science ®Google Scholar
• Larsson M, Fonteneau JF, Bhardwaj N. Cross-presentation of cell-associated antigens by dendritic cells. Curr Top Microbiol Immunol 2003; 276: 261–75
   Google Scholar
• Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci USA 2000; 97: 14590–5
   PubMed Web of Science ®Google Scholar
• Harshyne LA, Watkins SC, Gambotto A, et al. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001; 166: 3717–23
   PubMed Web of Science ®Google Scholar
• Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359–68
   PubMed Web of Science ®Google Scholar
• Regnault A, Lankar D, Lacabanne V, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189: 371–80
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Regnault A, Kleijmeer M, et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1: 362–8
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Krasovsky J, Williamson B, et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002; 195: 125–33
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 2002; 99: 13009–13
   PubMed Web of Science ®Google Scholar
• Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110: 71–9
   PubMed Web of Science ®Google Scholar
• Chaperot L, Manches O, Mi QJ, et al. Differentiation of antitumor cytotoxic T lymphocytes from autologous peripheral blood lymphocytes in non-Hodgkin's lymphomas. Br J Haematol 2002; 119: 425–31
   Google Scholar
• Chaperot L, Chokri M, Jacob MC, et al. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia 2000; 14: 1667–77
   Google Scholar
• Angel J, Chaperot L, Molens JP, et al. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine 2007; 25: 3913–21
   PubMed Web of Science ®Google Scholar
• Bhardwaj N, Bender A, Gonzalez N, et al. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J Clin Invest 1994; 94: 797–807
   PubMed Web of Science ®Google Scholar
• Lui G, Manches O, Chaperot L, et al. Preparation of purified lymphoma cells suitable for therapy. Cytotherapy 2004; 6: 235–43
   PubMed Web of Science ®Google Scholar
• Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 2003.
   Google Scholar
• Hoffmann PR, deCathelineau AM, Ogden CA, et al. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J Cell Biol 2001; 155: 649–59
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949–54
   PubMed Web of Science ®Google Scholar
• Russo V, Zhou D, Sartirana C, et al. Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells. Blood 2000; 95: 3473–7
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115: 807–11
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581–7
   PubMed Web of Science ®Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738–43
   PubMed Web of Science ®Google Scholar
• Franki SN, Steward KK, Betting DJ, et al. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood 2008; 111: 1504–11
   PubMed Web of Science ®Google Scholar